首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma
【24h】

ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma

机译:ProteinChip阵列分析用于鉴定鼻咽癌与疾病和化学治疗有关的生物标志物

获取原文
       

摘要

Background: We previously used ProteinChip array profiling analysis to discover a serum biomarker associated with nasopharyngeal carcinoma (NPC). In this study, we used the same method to examine other biomarkers associated with NPC and response to chemotherapy (CT) in NPC patients.Methods: We performed ProteinChip array analysis in 209 serum samples from 66 relapsed patients before and after salvage CT with gemcitabine and cisplatin or etoposide and cisplatin combinations, 11 patients in remission, and 35 healthy individuals. Intensities of the biomarker peaks were correlated with CT response of the patients and other clinical parameters.Results: We discovered 13 candidate biomarkers associated with different clinical parameters. Two biomarkers (2803 and 3953 Da) were significantly increased in patients compared with controls at all stages of disease. Analysis of pre- and post-CT paired serum samples revealed 7 biomarkers correlated with impact of CT. Of these 7 biomarkers, 2 (2509 and 2756 Da) were significantly increased and 5 (7588, 7659, 7765, 7843, and 8372 Da) were significantly decreased post-CT in either 1 or both CT cohorts. Four biomarkers from pre-CT sera were correlated with CT response, with 3 (2950, 13 510, and 14 855 Da) being significantly decreased and 1 (6701 Da) significantly increased in patients who did not respond to CT. Tandem mass spectrometric sequencing and/or immunoaffinity capture assay identified the 3953 Da biomarker as a fragment of interα-trypsin inhibitor precursor and 7765 Da biomarker as platelet factor-4.Conclusions: Treatment-associated serum biomarkers found might serve to triage NPC patients for appropriate CT treatment.
机译:背景:我们以前使用ProteinChip阵列分析来发现与鼻咽癌(NPC)相关的血清生物标志物。在这项研究中,我们使用相同的方法检查了NPC患者中与NPC相关的其他生物标志物以及对化疗(CT)的反应。方法:我们在66例复发患者中使用吉西他滨和吉西他滨进行了209份血清样本进行了蛋白质芯片分析。顺铂或依托泊苷和顺铂组合,缓解的患者11例,健康个体35例。结果:我们发现了13种与不同临床参数有关的候选生物标志物。与疾病各个阶段的对照相比,患者的两种生物标记物(2803和3953 Da)显着增加。 CT之前和之后配对的血清样品的分析显示7种生物标志物与CT的影响相关。在这1个或全部两个CT队列中,在这7种生物标志物中,有2种(2509和2756 Da)显着增加,而5种(7588、7659、7765、7843和8372 Da)显着降低。 CT之前血清中的四种生物标志物与CT反应相关,对CT无反应的患者中3种(2950、13510和14855 Da)显着降低,1(6701 Da)显着增加。串联质谱测序和/或免疫亲和捕获测定法鉴定出3953 Da生物标志物为间-胰蛋白酶抑制剂前体的片段,而7765 Da生物标志物为血小板因子4。结论:发现与治疗相关的血清生物标志物可能有助于对NPC患者进行适当的分类。 CT治疗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号